TAVR in patients with end stage liver and renal disease: Lifesaving and increasing transplant eligibility.

Abstract

Key Points Data regarding outcomes of transcatheter aortic valve replacement (TAVR) in end‐stage renal disease (ESRD) and/or end‐stage liver disease (ESLD) with severe symptomatic aortic stenosis (AS) is limited. In well‐selected group of patients with ESRD or ESLD, TAVR seems to have same short‐term mortality as control group with an increased trend for long‐term mortality as expected. Thus, TAVR is an option for AS with ESRD and/or ESLD in order to overcome cardiac barriers to solid organ transplantation. There is need to for larger studies to evaluate TAVR for AS in pretransplant patients with ESLD and ESRD, particularly as a separate cohort.